Topical NSAIDs may provide modest visual benefits as adjunctive therapy for diabetic macular edema (DME), according to a systematic review.
2
The review analyzed six studies involving 446 patients and 892 eyes, focusing on the effects of NSAIDs alongside anti-VEGF therapy.
3
Pooled analysis showed a statistically significant improvement in best-corrected visual acuity with NSAID therapy, but clinical relevance is uncertain.
4
Anatomical outcomes, including central macular thickness and macular volume, did not show statistically significant benefits from NSAID treatment.
5
The authors call for further exploration and larger studies to clarify the long-term efficacy and safety of topical NSAIDs in DME management.
AI offers meaningful opportunities to improve efficiency in ophthalmic ASC coding and revenue cycle workflows, but accurate reimbursement still depends on structured review and oversight.
